Gefitinib had been permitted by NIH bureau in Taiwan to treat patients with lung adenocarcinoma with susceptible EGFR mutation as the first-line therapy based on several phase III studies since June 2011 [1–4]. This evidence concerns the gene EGFR and lung adenocarcinoma.